OAKVILLE, ON, Sept. 7 /PRNewswire-FirstCall/ -- Excel-Tech Ltd. ("XLTEK") (TSX - "NRV"), a leading manufacturer of proprietary devices used to monitor the central and peripheral nervous systems, will release financial results for its second quarter on Thursday, September 14th, 2006 before market open. Following the release, XLTEK will hold a conference call at 10:00am (ET) hosted by Mr. John Mumford, President and Chief Executive Officer and Mr. Peter Kastelic, Chief Financial Officer.
DATE: Thursday, September 14th, 2006
TIME: 10:00 am, Eastern Time
DIAL IN NUMBER: 416-644-3417 or 1-800-814-4859
TAPED REPLAY: 416-640-1917 or 1-877-289-8525
(Available until September 21, 2006)
REFERENCE NUMBER: 21201523 followed by the number sign
WEBCAST: A live audio webcast of the call will be available at
http://www.xltek.com/. Webcast attendees are welcome to listen
to the conference in real-time or on-demand at their
convenience. The webcast will be archived for 90 days.
Please connect to this website at least 15 minutes
prior to the conference call to ensure adequate time
for any software download that may be needed to hear
the webcast.
Forward-Looking Statements:
Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's filings.
